OptimizeRx(OPRX) - 2025 Q3 - Quarterly Results

Financial Performance - Q3 2025 revenue increased 22% year-over-year to $26.1 million, up from $21.3 million in Q3 2024[5] - Q3 2025 gross profit rose 30% year-over-year to $17.5 million, compared to $13.4 million in Q3 2024[5] - GAAP net income for Q3 2025 was $0.8 million, or $0.04 per share, reversing from a net loss of $(9.1) million, or $(0.50) per share in Q3 2024[5] - Non-GAAP net income for Q3 2025 totaled $3.9 million, or $0.20 per diluted share, compared to $2.3 million, or $0.12 per diluted share in Q3 2024[5] - Adjusted EBITDA for Q3 2025 increased to $5.1 million, up from $2.7 million in the same period last year[5] - Net revenue for the three months ended September 30, 2025, was $26,067 million, a 22.5% increase from $21,309 million in the same period of 2024[24] - Gross profit for the nine months ended September 30, 2025, reached $49,495 million, compared to $37,355 million for the same period in 2024, reflecting a 32.4% increase[24] - The company reported a net income of $779 million for the three months ended September 30, 2025, compared to a net loss of $9,124 million in the same period of 2024[24] - Non-GAAP net income for the nine months ended September 30, 2025, was $9,960 million, compared to $6,200 million for the same period in 2024, an increase of 60.3%[29] - Adjusted EBITDA for the nine months ended September 30, 2025, was $12,326 million, compared to $2,882 million for the same period in 2024, indicating a substantial increase[30] Guidance and Projections - Full year 2025 revenue guidance increased to a range of $105 million to $109 million, with adjusted EBITDA guidance of $16 million to $19 million[1][7] - 2026 revenue guidance introduced at a range of $118 million to $124 million, with adjusted EBITDA expected between $19 million and $22 million[1][7] Cash and Operating Activities - Cash and cash equivalents as of September 30, 2025, totaled $19.5 million, up from $13.4 million as of December 31, 2024[5] - Cash provided by operating activities for the nine months ended September 30, 2025, was $11,627 million, significantly higher than $4,691 million in the same period of 2024[26] - The company reported a net increase in cash and cash equivalents of $6,139 million for the nine months ended September 30, 2025, compared to $2,274 million in the same period of 2024[26] Operating Expenses - Operating expenses decreased to $15,466 million for the three months ended September 30, 2025, down from $22,009 million in the same period of 2024, a reduction of 29.8%[24] - Total operating expenses for the nine months ended September 30, 2025, were $46,371 million, down from $54,695 million in the same period of 2024, a decrease of 15.2%[24] Revenue Metrics - Net revenue retention for the twelve months ended September 30, 2025, was 120%, down from 127% in the previous year[6] - Average revenue per top 20 pharmaceutical manufacturer increased to $3,073, compared to $2,874 in the prior year[6]